Updated efficacy data on glofitamab step-up dosing in NHL

Glofitamab in R/R NHL: How does step-up dosing compare with fixed dosing?Подробнее

Subcutaneous epcoritamab in R/R B-cell NHLПодробнее

NP30179: Glofitamab monotherapy in R/R NHLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

An update on the EPCORE NHL-1 trialПодробнее

Bispecifics in NHL: epcoritamab and glofitamabПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

What is the rationale behind step-up dosing of glofitamab in patients with MCL?Подробнее

Glofitamab step-up dosing in R/R MCLПодробнее

Bispecific antibodies in NHL: current insights and ongoing studiesПодробнее

Safety and efficacy of plamotamab in the treatment of non-Hodgkin lymphoma subtypesПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Phase II study of epcoritamab in R/R LBCLПодробнее

Preliminary results from NP40126: Glofitamab and R-CHOP in NHLПодробнее

Safety and efficacy of golcadomide (CC-99282) in the treatment of R/R NHLПодробнее

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCLПодробнее

Two-year follow-up data of a Phase I study investigating zamtocabtagene autoleucel in R/R NHLПодробнее

Efficacy and safety of M-Pola for R/R B-cell NHLПодробнее

Evaluating RO7443904 in combination with glofitamab in patients with R/R NHLПодробнее